Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Urinary Bladder Neoplasms 41Non-Muscle Invasive Bladder Neoplasms 25Colorectal Neoplasms 21Carcinoma, Transitional Cell 17Anus Neoplasms 17Neoplasm Metastasis 12Carcinoma, Hepatocellular 11Appendiceal Neoplasms 11Stomach Neoplasms 10Peritoneal Neoplasms 9Pancreatic Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Neoplasms 7Lung Neoplasms 6Colonic Neoplasms 6Rectal Neoplasms 5Liver Neoplasms 5Urologic Neoplasms 4Sarcoma 4Carcinoma 4Anal Canal Carcinoma 4Urologic Diseases 3Urogenital Neoplasms 3Urinary Bladder Diseases 3Recurrence 3Pseudomyxoma Peritonei 3Ovarian Neoplasms 3Neoplasms by Site 3Mesothelioma, Malignant 3Gastrointestinal Neoplasms 3

Interventions

veliparib 1tipifarnib 1pazopanib 1Mitozytrex 1Mitomycin 1Immunoglobulin G 1Geriatric Assessment 1Exercise 1Erlotinib Hydrochloride 1Disulfides 1Bevacizumab 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Neoplasm × Mitomycin × Clear all
NCT01017640 2016-07-11

Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled

Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡